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Abstract
Background: The average diagnostic sensitivity of exercise stress tests (ESTs) is lower than that of other non-invasive
cardiac stress tests. The aim of the study was to examine whether high-sensitivity cardiac troponin T (hs-cTnT) or
copeptin concentrations rise in response to inducible myocardial ischaemia and may improve the diagnostic accuracy of
ESTs.
Methods and results: An EST was performed stepwise on a bicycle ergometer by 383 consecutive patients with
suspected or progression of coronary artery disease (CAD). In addition venous blood samples for measurement of
hs-cTnT and copeptin were collected prior to EST, at peak exercise, and 4 h after EST. Coronary angiography was
assessed for all patients. Patients with significant CAD (n¼ 224) were more likely to be male and older compared to
patients with non-significant CAD (n¼ 169). Positive ESTwas documented in 125 (55.8%) patients with significant CAD
and in 69 (43.4%) patients with non-significant CAD. Copeptin and hs-cTnT concentrations at baseline were higher in
patients with significant CAD (copeptin: 10.8 pmol/l (interquartile range (IQR) 8.1–15.6) vs 9.4 pmol/l (IQR 7.1–13.9);
p¼ 0.04; hs-cTnT: 3.0 ng/l (IQR <3.0–5.4) vs <3.0 ng/l (IQR <3.0); p¼ 0.006). Hs-cTnT improved sensitivity (61.6% vs
55.8%), specificity (67.7% vs 56.6%) and the positive predictive value (PPV) (72.3% vs 64.4%) and negative (55.2% vs
47.6%) predictive value (NPV) of EST. Copeptin could not improve sensitivity (55.4% vs 55.8%) and reduced specificity,
PPV and NPV.
Conclusions: The measurement of hs-cTnT during EST improves sensitivity, specificity, and positive and negative
predictive values. In contrast, measurement of copeptin does not improve diagnostic sensitivity and reduces specificity.
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Introduction
Coronary artery disease (CAD) is the leading cause of
morbidity and mortality in the industrialised world.1
Due to demographic changes, the number of patients
with CAD will increase over the coming years. The
identiﬁcation of patients with CAD from among the
large number of elective patients with chest discomfort
represents a daily clinical challenge. Accurate diagnosis
and elective assessment of both symptomatic and
asymptomatic patients with suspected CAD could
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lead to reduced mortality and thus, it is of substantial
interest.1
The exercise stress test (EST) is the most common
type of noninvasive diagnostic tool for the detection of
myocardial ischaemia, because of its accessibility and
cost eﬃciency.2 There is a wide variation in the sensi-
tivity and speciﬁcity of exercise electrocardiograms
(ECGs), depending on the pretest probability (mean
sensitivity, 68% 16% and mean speciﬁcity,
77% 17%).3,4 The average sensitivity of the EST for
detecting myocardial ischaemia is considerably lower
than that of other noninvasive cardiac stress tests.5
Various biomarkers for the assessment of exercise-
induced myocardial ischaemia in stable CAD have been
investigated, but to date none have been shown to
improve the diagnostic accuracy of EST.6–9
Substantial progress in assay technologies has led to
high-sensitivity (hs) assays for cardiac troponin
(cTnT), which can detect myocardial necrosis earlier
than conventional assays.10 Studies have shown that
hs-assays can determine minimal changes in cTnT con-
centrations with the required accuracy in serum from
healthy individuals.11,12 In patients with CAD lately,
hs-cTnT was detected (above 3 ng/l) in 78% and 23%
of patients even showed values above the conventional
99th percentile (13.5 ng/l). These result implicate the
role of hs-cTnT also in patients with stable CAD.13
Another early-onset biomarker is copeptin, which
reﬂects individual stress levels.21,28–33 Copeptin is cose-
creted with arginine vasopressin from the posterior
pituitary. Previously published data have shown the
diagnostic and prognostic impact of copeptin measure-
ments used in combination with cTnT concentrations in
patients with acute myocardial infarction (AMI).12,18–21
The aim of the present study was to examine whether
hs measured cTnT or copeptin concentrations show an
increase in response to inducible myocardial ischaemia
during the EST. We also sought to determine if these
measurements improve the diagnostic accuracy of this
noninvasive cardiac stress test.
Methods
Study population
From January 2010–August 2011, 383 consecutive
patients with suspected CAD or suspected progression
of known CAD and history of percutaneous coronary
intervention (PCI) or coronary artery bypass grafting
(CABG) who were to undergo the EST were included in
the study. Clinical history, physical examination, 12-
lead ECG, laboratory tests, echocardiography, and cor-
onary angiography were assessed for all patients.
Exclusion criteria were AMI, unstable angina pectoris,
acute heart failure, severe aortic stenosis. 47.8%
(n¼ 183) of the patients showed CAD in their patient
history. Altogether 137 (35.8%) patients underwent a
previous PCI and 46 (12.0%) patients had a CABG
previously.
Informed written consent was obtained from all
patients for each investigation, as well as approval by
the ethical board of the state of Hessen, Germany
(FF31/2010). The investigation conforms to the prin-
ciples outlined in the Declaration of Helsinki.
EST
The EST was performed stepwise on a bicycle ergometer
in the erect position according to the current guidelines
(World health organisation (WHO) scheme 50/25) start-
ing with 25 or 50W, rising 25 or 50W every 2min.9 A
standard 12-lead ECG was recorded regularly prior to,
during every load level, and after the EST. Additionally,
patients were monitored continuously by a six-lead
ECG. A signiﬁcant ST-segment change was deﬁned by
either a 0.1mV horizontal or down-sloping depression
or a 0.1mV ST-segment elevation 60–80ms after the
J-point at the end of the QRS time. ECGs were recorded
with a 1mV/10mm and 50mm/s stylus deﬂection.
Criteria for a positive result from the EST were
ST-segment changes as mentioned above or onset of
angina pectoris during the EST. Stop criteria were rele-
vant ST-segment changes, angina pectoris, severe dys-
pnoea and exhaustion, as well as signiﬁcant
cardiovascular disorders such as maximum heart rate,
severe hypertension (>220mm Hg systolic), and severe
arrhythmias (ventricular tachycardia or arterioventri-
cular block >1). The highest maximum heart rate
was individually estimated by the formula 220–age
(years).4 Two independent cardiologists adjudicated
the ﬁnal EST result. If there was disagreement about
the EST result, a third cardiologist was involved.
Coronary angiography
Coronary angiograms were provided for each patient
after the EST according to standard clinical practice.
The indication of the coronary angiography was not
only based on the results of EST, but on guideline-
based clinical history or prior non-invasive diagnostics.
Signiﬁcant coronary artery disease was deﬁned as a
stenosis of at least one coronary artery exceeding 70%.
Revascularisation, if possible, was performed by PCI
or, regarding the severity of CAD, by CABG
afterwards.
Laboratory assessment
Venous blood samples were collected in plain tubes for
the determination of hs-cTnT and copeptin levels prior
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to the EST, at peak exercise, and at 4 h after the EST.
This time point could be veriﬁed by previous data
showing the highest release of troponin 3–4 h after exer-
cise tests.22 Serum was processed immediately and
frozen at 80 C until assayed.
The cTnT was measured in serum with the hs elec-
tro-chemiluminescence immunoassay (hs-cTnT assay,
Elecsys Analyzer 2010; Roche Diagnostics,
Mannheim, Germany). The limit of blank (LoB) for
the hs-cTnT assay is 3.0 ng/l, the limit of detection
(LoD) is 5 ng/l with the 99th percentile at a concentra-
tion of 14.0 ng/l. The lowest concentration measurable
with a coeﬃcient of variation (CV) <10% for this assay
is 13.5 ng/l.12 Copeptin was measured in serum by sand-
wich immunoluminometric assay (CT-proAVP;
ThermoFisher, Henningsdorf/Berlin, Germany). The
LoB for the copeptin assay is 2.5 pmol/l, the LoD is
3.2 pmol/l, with the 99th percentile at a concentration
of 13.5 pmol/l. The lowest concentration measurable
with a CV< 10% for this assay is down to 5.0 pmol/l.16
We counted an increase of 10% of the baseline
values as a signiﬁcant increase.
Statistical analysis
All data for continuous variables are expressed as
mean standard deviation (SD) or as median and
interquartile range (IQR) as appropriate. Categorical
variables are reported as number and percentage.
After testing for normal distribution by Kolmogorov-
Smirnov test, values were compared by unpaired
Student’s t-test or by Mann-Whitney test. Fisher’s
exact test or chi-square test was used for categorical
variables with nominal scales. To evaluate test improve-
ment due to hs-cTnT and copeptin levels, the area
under the curve (AUC) of the receiver-operating char-
acteristic (ROC) curve was plotted. To compare the
AUCs a c-statistic was calculated. All statistical tests
were two-tailed, and p< 0.05 was considered to indicate
statistical signiﬁcance. For all statistical analyses, the
statistical software SPSS 19.0 (Statistical Package for
the Social Sciences, Chicago, Illinois, USA) for
Windows was used.
Results
Study population
The study enrolled 383 patients (224 with signiﬁcant
CAD and 159 with non-signiﬁcant CAD, as revealed
by angiography). Patients who required coronary
revascularisation with PCI or CABG were assigned to
the signiﬁcant CAD group. Patients without need for
revascularisation were assigned to the non-signiﬁcant
CAD group. Signiﬁcant CAD was deﬁned as
angiographic-estimated coronary artery stenoses caus-
ing myocardial ischaemia. Non-signiﬁcant CAD was
deﬁned as absence of CAD or angiographic-estimated
coronary artery stenosis without causing myocardial
ischaemia. The baseline characteristics of all patients
are summarised in Table 1.
Baseline and patient characteristics
Patients with signiﬁcant CAD were more likely to be
male and older, and they had more arterial hyperten-
sion compared to patients without CAD. The
Framingham Risk Score (FRS) correlated signiﬁcantly
with CAD (r¼ 0.121, p¼ 0.036) and with hs-cTnT
increase (r¼ 0.140; p¼ 0.015). No correlation could
be observed between FRS and copeptin increase
(r¼ 0.061; p¼ 0.291).
EST
There were no diﬀerences in exercise capacity (CAD
119.0 38.4W vs nonsigniﬁcant CAD 121.4 43.0W;
p¼ 0.57) between the two groups. The EST showed a
positive result in 125 (55.8%) patients with signiﬁcant
CAD and in 69 (43.4%) patients with nonsigniﬁcant
CAD (Table 2). This showed a low sensitivity
of 55.8% and a speciﬁty of 56.6%. A total of
39 (10.2%) patients reached their maximum heart
rate, which can be explained by either symptoms or
ECG changes before that point or by being on
beta blocker medication. Nevertheless out of these
39 patients, 22 (56.4%) showed signiﬁcant CAD.
Out of these 22 patients, 17 (77.9%) patients had
a positive EST. This demonstrates that in patients
reaching their maximum heart rate a positive EST is
more likely to prove signiﬁcant CAD than patients
without reaching their maximum heart rate and posi-
tive EST.
Laboratory measurement
The hs-cTnT baseline concentrations (CAD 3.0 ng/l,
IQR <3.0–5.4 vs nonsigniﬁcant CAD <3.0 ng/l, IQR
<3.0; p¼ 0.006) and copeptin baseline concentrations
(10.8 pmol/l, IQR 8.1–15.6 vs 9.4 pmol/l, IQR 7.1–13.9;
p¼ 0.04) were signiﬁcantly higher in patients with
CAD.
The hs-cTnT concentrations increased at at least one
of the prespeciﬁed time points irrespective of the EST
result in 138 (61.6%) patients with CAD and in 53
(33.3%) patients with nonsigniﬁcant CAD (Figure 1).
In patients with CAD, there was no diﬀerence in the
increase in hs-cTnT levels in patients with a positive
EST result compared to those with a negative EST
result (82 (65.6%) vs 56 (56.6%); p¼ 0.21). In patients
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with nonsigniﬁcant CAD, no diﬀerence in hs-cTnT con-
centrations was observed irrespective of the EST results
(26 (37.7%) vs 27 (30.0%); p¼ 0.39). A signiﬁcant
increase in hs-cTnT concentrations was seen more
often in patients with multivessel CAD compared to
patients with one-vessel disease or without signiﬁcant
CAD (143 (64.4%) vs 48 (29.8%); p< 0.001). The hs-
cTnT measurements during EST showed improved sen-
sitivity (61.6% vs 55.8%), speciﬁcity (67.7% vs 56.6%),
and, therefore, the positive predictive value (PPV)
(72.3% vs 64.4%) and negative (55.2% vs 47.6%) pre-
dictive values (NPV) of EST (Table 3).
Copeptin concentrations increased at at least one of
the prespeciﬁed time points in 124 (55.4%) patients with
CAD and 92 (57.9%) patients with non-signiﬁcant CAD
(Figure 2). Regarding the EST result, there was no dif-
ference in the increase in copeptin levels in patients with
CAD (positive EST: 61 (48.8%) vs negative EST: 63
(63.6%); p¼ 0.03) compared to thosewith nonsigniﬁcant
CAD (positive EST: 37 (53.6%) vs negative EST: 55
(61.1%); p¼ 0.43). The hs-cTnT and copeptin
concentrations are displayed in Figures 1 and 2.
Copeptin measurement did not improve sensitivity
(55.4% vs 55.8%), and it reduced the speciﬁcity (42.1%
vs 56.6%) and positive (57.4% vs 64.4%) and negative
(40.1% vs 47.6%) predictive values of the EST (Table 3).
Regarding the ROC curves, hs-cTnT determination
during the EST provided the best result, with an AUC of
0.646 (95% conﬁdence interval (CI) 0.59–0.70;
p< 0.001) vs EST with an AUC of 0.56 (95% CI 0.50–
0.62; p¼ 0.038) and copeptin with an AUC of 0.55 (95%
CI 0.49–0.61; p¼ 0.09) (Figure 3). The AUC of all three
parameters were shown to be of signiﬁcant diﬀerence
due to the c-statistics (p< 0.001). AUC of hs-cTnT
ruled out EST (p¼ 0.02) and copeptin (p< 0.001).
Discussion
The number of patients with cardiovascular disease is
growing steadily.23 Consequently, suspected CAD is
one of the most frequent reasons for medical consult-
ation. The EST is widely used, but it has considerably
Table 1. Baseline characteristics
Variables
CAD Non-significant CAD
p valuen¼ 224 (58.5) n¼ 159 (41.5)
Men, n (%) 189 (84.4) 107 (67.3) <0.001
Age, mean (SD) 64.7 (9.9) 60.5 (12.5) <0.001
Cardiovascular risk factors, n (%)
Hypertension 199 (88.8) 118 (74.2) <0.001
Diabetes 70 (31.3) 39 (24.5) 0.17
Hyperlipoproteinaemia 170 (75.9) 114 (71.7) 0.18
Current smoker 32 (14.3) 38 (23.9) 0.93
Familial predisposition 68 (30.4) 49 (30.8) 0.91
Obesity 91 (40.6) 65 (40.9) 0.83
Left ventricular function, mean (SD) 54.7 (8.3) 56.1 (8.1) 0.12
Laboratory measurements, median (IQR)
Glomerular filtration rate 91.0 (IQR 77.0–107.8) 95.5 (IQR 81.3–112.8) 0.06
Creatinine 0.9 (IQR 0.8–1.0) 0.8 (IQR 0.7–0.9) 0.005
Hs-cTnT <3.0 (IQR <3.0–5.4) <3.0 (IQR <3.0) 0.006
Copeptin 10.8 (IQR 8.1–15.6) 9.4 (IQR 7.1–13.9) 0.04
Medication, n (%)
Beta blocker 179 (79.9) 92 (57.9) <0.001
Digitalis 1 (0.4) 1 (0.6) >0.99
ASA 190 (84.8) 82 (51.6) <0.001
Statins 174 (77.7) 68 (42.8) <0.001
ACE inhibitor 180 (80.4) 94 (59.1) <0.001
Diuretics 83 (37.1) 40 (25.2) 0.28
ASA: acetylsalicylic acid; ACE: angiotensin-converting enzyme; CAD: coronary artery disease; IQR: interquartile range; SD: standard
deviation
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low diagnostic accuracy. Improvements in the diagnostic
accuracy of the EST are of major clinical and health
system importance. We therefore evaluated whether
additional measurements of hs-cTnT and copeptin
levels would improve the diagnostic accuracy of the EST.
The new generation of troponin assays has a higher
analytical sensitivity and the ability to detect even
minor releases of cTnT; using one of these hs-assays,
our study showed an improvement in the diagnostic
accuracy of the EST by additional measurements of
hs-cTnT during the EST. Previously published data
demonstrated that cTnT increases proportionately
after exercise stress with the degree of myocardial
ischaemia found in nuclear imaging.24 These data sup-
port our results and show that hs-cTnT concentrations
increased below the 99th percentile signiﬁcantly in
patients with multi-vessel CAD while they underwent
the EST compared to patients with one-vessel CAD
that resulted from a greater myocardial ischaemia.24,25
In contrast, approximately one-third of the patients
without signiﬁcant CAD showed increased hs-cTnT
concentrations below the 99th percentile during the
EST. It is also known that cTnT is released
independently of CAD during extreme physical stress
or high ventricular rates.26 The elevation of hs-cTnT
levels in the absence of obstructive CAD might there-
fore be explained by the fact that physical stress is
accompanied by higher blood pressures and higher
heart rates, which may eventually lead to myocardial
necrosis or apoptosis.27
In our cohort, baseline copeptin concentrations were
higher in patients with CAD. During the EST, patients
with signiﬁcant CAD did not show an increase in
copeptin concentrations more often than patients with-
out signiﬁcant CAD. Measurement of copeptin concen-
trations during the EST was not of additive value for
making a diagnosis of CAD. As a biomarker, copeptin
appears to be related more to individual stress levels
than to myocardial ischaemia. This is in line with pre-
vious studies, which showed elevations in copeptin
levels due not only to myocardial ischaemia, but also
due to stroke, septic shock, heart failure, or other
stress-related conditions such as Tako-Tsubo cardio-
myopathy.28–31 Previous studies also indicated that
copeptin might function as an outcome parameter
after resuscitation or myocardial infarction.18,32
Table 2. Procedural and laboratory characteristics
Variables
CAD Non-significant CAD
p valuen¼ 224 (58.5%) n¼ 159 (41.5%)
Watt, mean (SD) 119.0 38.4 121.4 43.0 0.57
Reason for halting EST, n (%)
Angina pectoris 99 (44.2) 53 (33.3) 0.03
Dyspnoea 52 (23.2) 40 (25.2) 0.72
Exhaustion 135 (60.3) 102 (64.2) 0.46
Hypertensive disorder 17 (7.6) 17 (10.7) 0.37
ST-segment changes, n (%) 108 (48.2) 56 (35.2) 0.01
Positive EST result, n (%) 125 (55.8) 69 (43.4) 0.01
Haemodynamic parameters, mean (SD)
Heart rate baseline (bpm) 67.1 13.2 70.4 13.8 0.04
Heart rate maximum (bpm) 116.6 22.0 122.6 22.7 0.02
Systolic blood pressure baseline (mm Hg) 128.1 21.8 127.7 17.5 0.99
Systolic blood pressure maximum (mm Hg) 177.9 30.2 184.8 32.1 0.02
Diastolic blood pressure baseline (mm Hg) 78.7 12.1 81.1 11.7 0.07
Diastolic blood pressure maximum (mm Hg) 86.6 16.1 87.9 15.0 0.22
Hs-cTnT increase, n (%) 138 (61.6) 53 (33.3) <0.001
Hs-cTnT at maximum stress <3.0 (IQR 3.0–6.5) <3.0 (IQR <3.0–3.5) <0.001
Hs-cTnT 4 h after EST 3.4 (IQR <3.0–7.7) <3.0 (IQR <3.0–3.7) <0.001
Copeptin increase, n (%) 124 (55.4) 92 (57.9) 0.68
Copeptin at maximum stress 14.9 (IQR 9.7–26.8) 10.8 (IQR 8.5–18.9) 0.003
Copeptin 4 h after EST 11.7 (IQR 8.2–14.9) 9.6 (IQR 6.5–14.8) 0.006
CAD: coronary artery disease; EST: exercise stress test; hs-cTnT: high-sensitivity cardiac troponin T; SD: standard deviation.
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Increased copeptin levels correlated more strongly with
the peak exercise level than with obstructive CAD. This
conﬁrms the ﬁndings by Maeder and colleagues, who
reported that higher absolute exercise capacity and
higher exercise intensity are associated with greater
changes in copeptin concentrations.33
If the additional determination of hs-cTnT during
EST reduces false-positive and false-negative EST
results, then the number of unnecessary coronary
angiographies could be reduced, and patients with
CAD could be treated earlier. This would have major
implications for health care resources. However, a val-
idation needs to be performed in a large-scale, real-
world scenario to establish new work-up protocols for
the EST.
Limitations
The results of our study should be interpreted in the
context of several limitations. The EST results in pre-
vious studies as well as in our study show a very low
sensitivity and speciﬁcity, but provide insight in daily
clinical practice. The troponin concentrations in both
groups are mainly close to the LoB. Values below the
LoD have a higher imprecision (CV¼ 20%). The new
nano particle troponin assay provides an imprecision of
<10% at very low cTnT concentrations which would be
of interest.34 The availability of these new assays is
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Figure 1. Cardiac troponin T (cTnT) serum concentrations (median fold-change (interquartile range (IQR)) of all patients at baseline
and throughout the study. Grey bars indicate patients without coronary artery disease (CAD). Green bars indicate patients with CAD.
Circles indicate outlier data points. EST: exercise stress test.
Table 3. Test accuracy for diagnosis of coronary artery disease
(CAD)
Tests Sensitivity Specificity NPV PPV
Exercise stress test 55.8% 56.6% 64.4% 47.6%
Troponin T increase
At maximum stress 45.1% 72.3% 69.7% 48.3%
At 4 h after EST 51.8% 72.3% 72.5% 51.6%
At at least one of
the time points
61.6% 66.7% 72.3% 55.2%
Copeptin increase
At maximum stress 50.0% 45.3% 56.3% 39.1%
At 4 h after EST 30.8% 76.1% 64.4% 43.8%
At at least one of
the time points
55.4% 42.1% 57.4% 40.1%
EST: exercise stress test; NPV: negative predictive value; PPV: positive
predictive value.
Liebetrau et al. 689
limited and due to costs and time-consuming analysis
without clinical implications at the moment.
Conclusions
The EST alone has a low diagnostic accuracy for
CAD. Analysing hs-cTnT during the EST improves
the sensitivity and speciﬁcity, as well as the PPV and
NPV of the EST. In contrast, measurement of copep-
tin levels improves the diagnostic sensitivity of the
EST, but worsens the speciﬁcity and therefore the
PPV and NPV. Only hs-cTnT measurements improve
the diagnostic accuracy of the EST in patients with
suspected CAD.
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